<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296762</url>
  </required_header>
  <id_info>
    <org_study_id>P-636/08</org_study_id>
    <nct_id>NCT02296762</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition</brief_title>
  <official_title>Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Sirolimus Tablets 2 mg Under Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India
      and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy,
      adult,human subjects under Fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized, two-treatment, two-period, two-sequence, cross over, single dose,
      oral bioequivalence study of Sirolimus tablets 2 mg under Fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>predose (0.00) (0.00) and 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 3.75, 4.00, 4.50, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours post-dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sirolimus tablets 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapamune</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus tablets 2 mg</description>
    <arm_group_label>Sirolimus tablets 2 mg</arm_group_label>
    <arm_group_label>Rapamune</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Provide written informed consent

        ii. Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive)
        weighing at least 50 kg

        iii. Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight
        in Kg/height in m2

        iv. Must be of normal health as determined by medical history, physical examination and
        laboratory investigation performed within 28 days prior to the commencement of the study.
        (Laboratory values must be within normal limits or considered by the physician /
        investigator to be of no clinical significance)

        v. Female Subjects

          -  Of child bearing potential practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms, foams,
             jellies, diaphragm, intrauterine device (IUD), or abstinence

          -  Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
             has been performed on the subject)

        Exclusion Criteria:

        i. Incapable of understanding the informed consent

        ii. Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg

        iii. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg

        iv. Oral temperature is below 95.0°F or above 98.6°F

        v. Pulse rate below 50/min or above 100/min

        vi. History of hypersensitivity or idiosyncratic reaction to investigational drug product
        or any other related drugs

        vii. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
        function

        viii. Consumption of grapefruit for the past ten days prior to the check-in, in each period

        ix. Regular smoker who has a habit of smoking more than nine cigarettes per day and has
        difficulty in abstaining from smoking during sample collection period

        x. Habit of alcoholism and difficulty in abstaining from alcohol during the sample
        collection period

        xi. Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee,
        chocolates and cola drinks) during the sample collection period

        xii. Intake of over the counter (OTC) or prescribed medications and enzyme modifying
        medication or systemic medication for the last 30 days before dosing

        xiii. Clinically significant abnormalities and / or with significant diseases

        xiv. Confirmed positive in alcohol screening

        xv. Confirmed positive in selected drug of abuse

        xvi. Participated in any other clinical investigation using experimental drug/donated blood
        in past 90 days before the date of start of study

        xvii. Confirmed positive in urine pregnancy test

        xviii. Female detected to be pregnant, breast feeding or who is likely to become pregnant
        during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Dwarakanath, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Pvt Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Pvt. Ltd</name>
      <address>
        <city>Balanagar, Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

